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Abstract
Background: In 2000, Ringertz et al described the first case of systemic anthrax caused by injecting heroin
contaminated with anthrax. In 2008, there were 574 drug related deaths in Scotland, of which 336 were associated
with heroin and or morphine. We report a rare case of septicaemic anthrax caused by injecting heroin
contaminated with anthrax in Scotland.
Case Presentation: A 32 year old intravenous drug user (IVDU), presented with a 12 hour history of increasing
purulent discharge from a chronic sinus in his left groin. He had a tachycardia, pyrexia, leukocytosis and an
elevated C-reactive protein (CRP). He was treated with Vancomycin, Clindamycin, Ciprofloxacin, Gentamicin and
Metronidazole. Blood cultures grew Bacillus anthracis within 24 hours of presentation. He had a computed
tomography (CT) scan and magnetic resonance imagining (MRI) of his abdomen, pelvis and thighs performed.
These showed inflammatory change relating to the iliopsoas and an area of necrosis in the adductor magnus.
He underwent an exploration of his left thigh. This revealed chronically indurated subcutaneous tissues with no
evidence of a collection or necrotic muscle. Treatment with Vancomycin, Ciprofloxacin and Clindamycin continued
for 14 days. Negative Pressure Wound Therapy (NPWT) device was applied utilising the Venturi™ wound sealing
kit. Following 4 weeks of treatment, the wound dimensions had reduced by 77%.
Conclusions: Although systemic anthrax infection is rare, it should be considered when faced with severe
cutaneous infection in IVDU patients. This case shows that patients with significant bacteraemia may present with
no signs of haemodynamic compromise. Prompt recognition and treatment with high dose IV antimicrobial
therapy increases the likelihood of survival. The use of simple wound therapy adjuncts such as NPWT can give
excellent wound healing results.
Background
Anthrax is believed to be the cause of the 5
th plague
described in the book of Exodus (chap 9:3). It is a zoo-
nosis affecting most herbivores, however, transmission
from human to human has never been documented
[1-3]. It is caused by Bacillus anthracis, a gram positive
spore forming bacillus. It occurs when Bacillus anthra-
cis’ endospores enter the body either through breaks in
the skin, ingestion or inhalation. Anthrax characterisa-
tion is based upon its original mode of transmission;
cutaneous, gastrointestinal and inhalational. Anthrax is
derived from the Greek word meaning coal after the
black skin lesions seen in its cutaneous form [1].
Anthrax remains relatively rare with between 20,000
and 100,000 cases occurring in the world annually [4]. It
is predominantly related to occupational exposure as
seen in farmers, veterinarians and people handling wool
[5]. Only a handful of anthrax cases have been seen in
Britain over the last decade. In 2006, a fatal case of
inhalation anthrax was reported in the Scottish borders
[6]. This was the first case of anthrax seen in nearly 30
years. In 2000, Ringertz et al described the first case of
systemic anthrax caused by injecting heroin contami-
nated with anthrax [7].
In 2008, there were 574 drug related deaths in Scot-
land, of which 336 were associated with heroin and or
morphine [8]. Of the 574 deaths, 197 (34%) occurred in
Greater Glasgow & Clyde. NHS Greater Glasgow and
Clyde covers the city of Glasgow and a population of
approximately (1.2 million) [9]. In 2000, it was estimated
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users (IVDU) [10]. Due to the risky behaviour associated
with illicit drug use, mortality rates in IVDU patients
have been estimated to be 12-22% higher than an age-
adjusted population [11-13].
In December 2009, the first case of fatal anthrax relat-
ing to intravenous drug abuse was documented in the
British media [14]. In total there were 47 confirmed
cases and 13 anthrax related deaths during this outbreak
[15,16]. Systemic anthrax infection is associated with
high mortality rates with 45% of patients with inhalation
anthrax ultimately dying from the infection [17,18].
Cutaneous anthrax infection, however, is not associated
with high mortality rates [19].
We present an interesting case of septicaemic anthrax,
in a patient with no evidence of septic shock, caused by
injecting heroin contaminated with anthrax in the UK.
In our case report, we discuss the clinical and pathologi-
cal aspects of the case, the use of wound therapy
adjuncts in promoting wound healing and review the
current literature.
Case Presentation
A 32 year old male who was a known IVDU, presented
with a 12 hour history of increasing swelling in his left
leg. He had a purulent discharge from a chronic sinus
in his left groin.
On examination, he had warm erythematous sinuses
in both groins. The left sinus was discharging foul smel-
ling pus. He had a tachycardia 120 bpm and pyrexia
38.2 degrees C, blood pressure (BP) 136/86. He was
alert and orientated to time, place and person. Blood
tests revealed a white cell count (WCC) of 15.9 × 10
9/l,
a C-Reactive Protein (CRP) of 21 mg/dl and blood cul-
tures were taken. He was treated with broad spectrum
antibiotics Vancomycin, Clindamycin, Ciprofloxacin,
Gentamicin and Metronidazole in line with the latest
advice from microbiology because of a recent outbreak
of anthrax in the local IVDU population. Within 24
hours of collection, all 6 blood culture bottles grew
gram positive organisms suggestive of Bacillus anthracis
and he was referred for consideration of surgery. The
cultured Bacillus anthracis organism was susceptible to
all the above antibiotics. Clinically there was no abscess
to drain so he had a computed tomography (CT) scan
of his abdomen, pelvis and thighs performed. This
showed loculated fluid and inflammatory change ante-
rior to the left psoas muscle extending down to the ilia-
cus [Figure 1]. In the pelvis, the left pectineus and
adductor magnus were oedematous possibly reflecting
muscle necrosis [Figure 2].
Given that he was clinically well his conservative man-
agement and monitoring continued. Over the next five
days there were signs of improvement with a reduction in
the inflammatory markers and no evidence of organ dys-
function. In consultation with colleagues in microbiology,
infectious diseases and public health a further CT scan
was performed to ensure that there was no collection to
drain as the limited local experience suggested that drai-
nage and debridement of collections and necrotic tissues
resulted in optimal management. This scan showed that
the retroperitoneal and thigh changes had improved
slightly. Within a further 24 hours he had developed an
area of cellulitis over the left thigh and lower abdomen
and a Magnetic Resonance Imaging (MRI) was carried
out. This showed diffuse oedematous change in the mus-
cles and subcutaneous fat of the left leg from the level of
the inguinal region to below the knee. After contrast,
there were areas which did not show evidence of contrast
enhancement with an irregular enhancing margin. The
absence of discrete high signal on the STIR images was
thought to represent areas of non-perfused musculature,
possible undergoing necrotic change [Figure 3].
He underwent an exploration of his left thigh. This
revealed chronically indurated subcutaneous tissues in
keeping with his long history of injecting into the area.
There was some oedematous fluid but no evidence of a
collection or necrotic muscle. Post-operatively he made
a steady recovery.
Treatment with Vancomycin, Ciprofloxacin and Clin-
damycin continued for 14 days. Negative Pressure
Wound Therapy (NPWT) device was applied utilising
the Venturi™ wound sealing kit. This followed the ther-
apy application technique first described by Chariker et
al using saline-moistened gauze, a silicone drain and
clear, semi-permeable adhesive film, together with lower
pressures, usually between 60-80 mmHg.
15
The dressings were changed three times per week and
wound exudate collection canisters changed as required
Figure 1 CT Abdomen and Pelvis. Loculated fluid and
inflammatory change anterior to the left psoas muscle.
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Ciprofloxacin 400 mg twice a day and continued with
NPWT. Following 4 weeks of treatment, the wound
dimensions had reduced from 300 cm3 [Figure 4] to 68
cm3 [Figure 5], a reduction in size of 77%. He remains
well and attends regular review at outpatient clinic.
Conclusions
We present an interesting case of septicaemic anthrax in
an intravenous drug user, who despite having B. anthra-
cis bacteraemia and severe cutaneous infection, displayed
no evidence of septic shock and made an uneventful
recovery following IV antibiotic therapy and surgical deb-
ridement. This case was part of a large outbreak of septi-
caemic anthrax infection in an IVDU population of 47
patients with a mortality rate of 27% [15].
Mortality associated with systemic anthrax infection is
well known to be high with 40% of the patients in the
2001 bioterrorist attacks dying from the infection [17].
Of the 10 patients in their series, 7 patients presented
with severe sepsis and grew B. anthracis on blood cul-
ture. Of the 7 patients with bacteraemia 4 died of acute
circulatory collapse. This suggests the presence of posi-
tive blood cultures foretells a high risk of mortality.
Doganay and colleagues described a series of 22 patients
presenting with cutaneous anthrax infection over a 7
year period [19]. Of these, 10 patients had severe infec-
tion and 2 patients suffered from septic shock. In con-
trast to our case, all patients with positive blood culture
had evidence of severe infection and septic shock. Of
interest, none of the patients in their series died from
anthrax.
It is believed this outbreak resulted from exposure to a
batch of contaminated heroin. This is suggested by the
geographical distribution and the occurrence of contem-
poraneous outbreaks within the city. McGuigan et al
reported a similar outbreak in 2000; however, the aetio-
logical agent is thought to have been Clostridium novyi
[13]. Street heroin in Britain is thought to originate
from Afghanistan [13,20]. Non-sterile methods for its
production, ‘cutting’ and transportation increase the risk
of contamination.
The lethal outbreak of Clostridium novyi in 2000
prompted the production of consensus guidelines for
treating severe cutaneous infection in IVDU patients. In
t h ec a s es e r i e sr e p o r t e db yM c G u i g a ne ta l ,t h ec o m -
monest organisms seen, were Clostridium novyi, Staphy-
lococcus aureus, group A beta-haemolytic streptococci
Figure 2 CT Abdomen and Pelvis. The adductor magnus which is oedematous possibly reflecting muscle necrosis.
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using an antimicrobial regimen of Flucloxacillin, Benzyl-
penicillin, Gentamicin, Clindamycin and Metronidazole
[13].
In 2001, Swartz published guidelines for the recogni-
tion and management of anthrax. He suggested using
ciprofloxacin 400 mg IV combined with a penicillin for
inhalation and severe cutaneous anthrax infection [21].
His recommendations were based on consensus guide-
lines published by Iglesby et al. The efficacy of cipro-
floxacin in anthrax had been poorly studied in humans,
however, in animal models excellent recovery has been
demonstrated despite the lack of an immune response
[22]. This finding led to the recommendation that all
patients surviving anthrax should continue antibiotic
therapy for 60 days.
The evidence published by McGuigan et al suggested
that of all the patients who were classified as a ‘definite’
diagnosis of Clostridium novyi, approximately 20% grew
an alternative organism. This suggests, even during a
recognised outbreak, the diagnosis of a particular infec-
tion based on clinical parameters alone is unreliable.
All IVDU patients presenting with severe cutaneous
infection were treated with Benzylpenicillin, Flucloxacil-
lin, Gentamicin, Clindamycin, Ciprofloxacin and Metro-
nidazole. In the case of penicillin allergy Vancomycin
was used in place of Benzylpenicillin and Flucloxacillin.
Once a causative agent was found, the antimicrobial
therapy was rationalised. The diagnosis of anthrax was
confirmed by isolation of Bacillus anthracis in early
blood cultures in some patients. This was supported by
PCR testing of blood or excised tissues at the Health
Protection Agency (HPA) Special Pathogens Reference
Unit (SPRU) at Porton Down.
NPWT is a non-invasive technology comprising a
negative pressure pump connected by a tube to a dres-
sing that occupies the wound cavity. The dressing is
sealed to the peri-wound skin using an adhesive film.
This provides a closed system, so that negative (sub-
atmospheric) pressure is generated at the wound/dres-
sing interface. NPWT is suitable for acute, chronic and
traumatic wounds as an adjunct to surgery [23]. Despite
NPWT appearing in the literature for over 50 years, the
physiological and molecular biological mechanisms by
Figure 3 MRI Pelvis and Thighs. An area of decreased signal inferior and lateral to the left femoral neurovascular bundle. This was suggestive
of tissue necrosis.
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Figure 5 Appearance of the wound following 4 weeks of NPWT.
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unknown [24].
Although systemic anthrax infection is rare, it should
be considered when faced with severe cutaneous infec-
tion in IVDU patients. The presence of Bacillus anthra-
cis on blood culture is normally associated with septic
shock and high rates of mortality; however, our case
suggests that these patients may not exhibit haemody-
namic compromise despite having significant bacterae-
mia. Prompt recognition and treatment with high dose
IV antimicrobial therapy increases the likelihood of sur-
vival. Adherence to antimicrobial prescribing guidelines
reduces the possibility of missing other potentially lethal
organisms. The use of simple wound therapy adjuncts
such NPWT can give excellent wound healing results
over a relatively short period.
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